Baudax Bio, Inc. Share Price

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Market Closed - OTC Markets 10:54:26 29/04/2024 pm IST 5-day change 1st Jan Change
0.01 USD -2.91% Intraday chart for Baudax Bio, Inc. -10.71% -54.55%
Sales 2021 1.08 90.08 Sales 2022 1.27 105.85 Capitalization 1.76M 147M
Net income 2021 -19M -1.58B Net income 2022 -58M -4.84B EV / Sales 2021 1,71,66,252 x
Net cash position 2021 6.35 529.99 Net Debt 2022 2.68 223.21 EV / Sales 2022 13,90,484 x
P/E ratio 2021
-0.76 x
P/E ratio 2022
-0.02 x
Employees 9
Yield 2021 *
-
Yield 2022
-
Free-Float 99.98%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Baudax Bio, Inc.

1 day-2.91%
1 week-10.71%
Current month-23.08%
1 month-23.08%
3 months-61.39%
6 months-93.55%
Current year-54.55%
More quotes
1 week
0.01
Extreme 0.01
0.01
1 month
0.01
Extreme 0.01
0.02
Current year
0.01
Extreme 0.01
0.05
1 year
0.01
Extreme 0.01
1.43
3 years
0.01
Extreme 0.01
1 624.00
5 years
0.01
Extreme 0.01
14 196.01
10 years
0.01
Extreme 0.01
14 196.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 01/19/01
Director of Finance/CFO 50 09/23/09
Corporate Officer/Principal 60 01/19/01
Members of the board TitleAgeSince
Director/Board Member 83 21/19/21
Chief Executive Officer 71 01/19/01
Chairman 68 21/19/21
More insiders
Date Price Change Volume
29/24/29 0.01 -2.91% 88,524
26/24/26 0.0103 -8.04% 14,336
25/24/25 0.0112 +6.67% 7,116
24/24/24 0.0105 -0.94% 6,065
23/24/23 0.0106 -5.36% 5,960

Delayed Quote OTC Markets, April 29, 2024 at 10:54 pm IST

More quotes
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
More about the company